Final safety findings from a randomized phase III trial of preoperative FU-based chemoradiation +/- weekly oxaliplatin as neoadjuvant therapy for patients with locally advanced rectal cancer: the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial

Reviewer: Christine Hill, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 7 de febrero del 2009

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

AACR: Advances Show Promise for Variety of Cancers

Dec 1, 2015

Press conference showcases potential treatments for cancers of the brain, pancreas, and prostate

ACCR: Oral Olaparib Plus Chemo Beneficial in Ovarian Cancer

Sep 11, 2014

Olaparib deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer

Excessive Neutropenia for Weekly Everolimus + Docetaxel

Apr 30, 2012

Dose-limiting neutropenia, variable drug clearance for patients with metastatic breast cancer